. 2020 May 26;11(21):1942–1952. doi: 10.18632/oncotarget.27600

Table 3. Patient Outcomes.

Patient ID-Pathology¹	Enrolled Dose (mg/m2)	On treatment date	Off treatment date²	Dose Limiting Toxicity	Best Response³	Number of cycles⁴	Reason Off Treatment⁵	Date of progression
1 - low grade astrocytoma NOS	550	4/30/2014	5/27/2015	yes	PR	14	Completed Therapy	9/1/2015
3 - pilocytic astrocytoma	550	9/29/2014	9/2/2015	no	SD	12	Completed Therapy	n/a
4 - pilocytic astrocytoma	550	10/16/2014	+	yes	SD	64	n/a	n/a
5 - PXA	420	12/4/2014	8/13/2015	yes	SD	9	Adverse event	n/a
6 - fibrillary astrocytoma	420	1/29/2015	12/28/2015	no	SD	12	Completed Therapy	n/a
7 - pilocytic astrocytoma	420	3/9/2015	5/31/2016	yes	SD	16	Patient decision^*	n/a
10 - ganglioglioma	420	8/20/2015	9/15/2016	no	SD	14	Disease progression	9/13/2016
11 - pilocytic astrocytoma	420	9/30/2015	2/13/2019	no	SD	44	Patient decision^*	n/a
12 - ganglioglioma	420	12/8/2015	2/11/2019	no	SD	41	Patient decision^*	4/19/2019
13 - pilocytic astrocytoma	420	12/31/2015	4/8/2016	no	PR	4	Adverse event	n/a
14- pilocytic astrocytoma	420	4/14/2016	5/17/2018	no	SD	27	Patient decision^*	n/a
15 -ganglioglioma	420	5/12/2016	+	no	SD	43	n/a	n/a
16 - ganglioglioma	420	6/15/2016	+	no	SD	42	n/a	n/a
17 -pilocytic astrocytoma	550	9/29/2016	+	no	PR	38	n/a	n/a
18 - PXA	550	10/3/2016	8/8/2018	no	CR	24	Patient decision^*	n/a
19 - pilocytic astrocytoma	550	11/10/2016	8/31/2018	no	SD	24	Patient decision^*	n/a
20 - pilocytic astrocytoma	550	1/11/2017	10/26/2018	no	PR	23	Adverse event	12/11/2018
21 - pilocytic astrocytoma	550	2/22/2017	4/25/2018	no	PR	15	Adverse event	12/10/2018
22- ganglioglioma	550	2/21/2017	11/8/2018	no	SD	22	Poor compliance	n/a

1. NOS = not otherwise specified; PXA = Pleomorphic Xanthoastrocytoma

2. + Indicates that the patient remains on treatment as of 8/31/2019

3. Best response by imaging. PR = partial response; SD = stable disease

4. Median number of cycles = 23

5. Completion of protocol is defined as completing 12 cycles therapy.

^*Patient decision to stop treatment with stable disease after 12 or more cycles; treatment was allowed to continue indefinitely as long as no toxicity, progression, or patient preference